The US Food and Drug Administration (FDA) has approved Mira’s new hormone tracker as an over-the-counter tool to predict menopause and evaluate fertility.
The Ovum Wand is an AI-powered device that provides accurate detection of the follicle-stimulating hormone (FSH) in urine to help monitor fertility and find possible causes of reproductive issues for women after 35.
From October, the product will be available to US customers. The tool aims to help women get an inside look into their full menstrual cycle, manage irregular cycles, PCOS, and hormone imbalances as well as monitor hormone levels for fertility treatments such as IVF and IUI.
A survey of 1,039 American women aged 40-65 has found that 45 per cent did not know the distinction between perimenopause and menopause.
Mira, a mobile health platform for monitoring reproductive health, is hoping that its Ovum Wand will provide information to help women understand these life stages and address the symptoms early.
Tracking the FSH is essential for women in their 20s, 30s, or 40s because it directly impacts their ability to get pregnant. To predict approaching menopause or track changes in fertility, a person needs to test over several days for two or more cycles.
Additionally, FSH tracking could also help monitor the effectiveness of hormone replacement therapy (HRT) to make it more targeted and personalised.
Mira allows users to safely monitor their FSH levels at home without the need for a blood test. Data points are saved and analysed to give personalised health insights and the users can also share the information with their medical provider.
“The Mira Ovum Wand further expands our capabilities in at-home hormone testing,” says Sylvia Kang, Mira CEO. “The launch reinforces Mira’s goal to support women throughout their lives by helping them understand their hormones at any age, be it puberty, adulthood, or later years.”
She adds: “This knowledge grants the ability to make informed fertility decisions and eliminates the dread associated with the word ‘menopause’, so that women can go through this journey with confidence and awareness.”
The company offers a line of hormone test wands. Like its predecessors, the new Ovum Wand is compatible with the Mira’s analyser and uses machine learning to track changing hormone patterns over time. The analyser can be connected to Mira App to display clear numerical data along with personalised insights on the user’s reproductive health.
For more info, visit miracare.com.
How we can address the gender imbalance in fertility testing
Everyone has heard of the female biological clock, but not many people know that male fertility declines throughout adulthood too
Although one in six couples globally have difficulty conceiving, infertility remains a woman’s social burden. We need to address male infertility, says Lily Elsner.
Infertility affects 186 million people worldwide and, despite everything society has led us to believe, one-third of infertility cases are caused by male reproductive issues.
Male infertility can be caused by low sperm production, abnormal sperm function or blockages that prevent the delivery of sperm. Some men may also experience fertility issues due to chronic health problems, illnesses and lifestyle choices.
How come no one talks about it? To date, fertility has been firmly cast as a “woman’s issue”, irrespective of men being half of the fertility equation.
Everyone has heard of the female biological clock, but not many people realise that male fertility declines throughout adulthood too. Research shows that men will generally see a 52 per cent decrease in fertility rate between their early 30s and their mid-to-late 30s.
“Male infertility, although often treatable, is a very taboo subject,” says Lily Elsner, co-founder and CEO of Jack Fertility.
“Because men don’t have the same relationship with their physicians as women do, they often don’t know they could do something about it.”
Culturally, it can also be hard for men to talk about having trouble conceiving as this can be seen as a lack of masculinity.
Research shows that the majority of men (73 per cent) are unlikely to talk about their infertility with others. In fact, 39 per cent are not likely to talk about their infertility at all.
Elsner, however, thinks we can change that. As the woman behind Jack Fertility’s at-home sperm test kit, she thinks talking openly about male infertility could go a long way towards addressing the gender imbalance in fertility testing.
“The whole point of femtech is to ensure women’s health is prioritised. By opening up the conversation around reproductive health and making it easy to assess male fertility, we can take some of the pressure off of women.
“Some men may not want to talk about their infertility still, but it’s an essential component of creating an equal world for all genders. I am tired of watching women shoulder the majority of infertility’s physical and emotional burden, and seeing men and non traditional families completely neglected in the medical and societal discourse surrounding fertility.”
A test like Jack, Elsner says, could give people that empowerment of having access to their health data and provide them with the tools to be able to make the right decision for them.
“A lot of men think of fertility as static, when really the male body is constantly creating sperm. With Jack, what we are trying to say is, ‘Actually, your fertility massively depends on your current health and chronic illnesses’.
“Our aim is to make it easy and convenient for all men to get reliable results about the status of their fertility, even if they are not considering starting a family. That’s part of why we named the company Jack – it’s cheeky and relatable.”
There are many fertility test on the market, but Elsner doesn’t see that as a bad thing.
“The rise of companies providing at-home sperm testing suggests a growing interest in male reproductive health, but it also signals a shift in attitudes, with fertility being recognised as an issue that affects both men and women equally,” she says.
“There are so many amazing companies out there working on fertility tests, but I think most of them are targeted a little bit further down the funnel. For us, it’s about getting men to take that first important step of getting tested. We just want them to have a chat with Jack.”
Jack Fertility is expected to launch later this year. To find out more, visit jackfertility.co.uk.
Partnership to pilot ‘cutting-edge’ embryo selection tool
The partnership is hoped to streamline laboratory operations with the potential future benefit of optimising the embryo selection process
The US fertility technology company Alife Health has teamed up with a network of laboratories to pilot an AI technology for embryo image capture and cataloguing.
The company’s partnership with Ovation Fertility aims to focus on streamlining laboratory operations with the potential future benefit of optimising the embryo selection process.
The technology could enable future “AI-powered” embryo selection.
Alife’s Embryo Assist software promises to help embryologists to create digital records of every embryo, with the added benefit of using the start-up’s clinical decision support algorithm to determine the best embryo for transfer.
Paxton Maeder-York, founder and CEO of Alife, said: “We are thrilled to join forces with Ovation, a leading laboratory network in the country, to showcase the transformative impact of Alife’s technology.
“Through this partnership, we aim to demonstrate how Alife’s advanced technology, powered by AI, can not only optimise clinic workflow, but also set a new standard in the precision and consistency of embryo selection.
“We look forward to contributing to Ovation’s commitment to excellence in fertility care.”
Matthew VerMilyea, vice president of scientific advancement at Ovation, added: “At Ovation, we strive to discover and leverage the most state-of-the-art technologies available to us in order to better improve patient outcomes.
“The Alife Embryo Assist software provides our laboratories with a structured digital approach to a rather manual and cumbersome process.
“I believe that by implementing Alife’s technology, we will see an improvement in lab efficiency and performance, which ultimately will help our network provide the best possible outcomes for every individual hoping to grow their family.”
The Embryo Assist software claims to allow embryologists to capture images of each embryo and streamline the embryo reporting process by eliminating the need to manually transcribe information between systems.
Alife expects the tool to “elevate” laboratory quality-control measures by providing an activity and audit trail for every embryo, viewable in real time.
Kitazato and IVF2.0 forge groundbreaking collaboration to revolutionise IVF with AI solutions
The collaboration aims to advance real-time sperm selection for intracytoplasmic sperm injection (ICSI) and embryo ranking
Kitazato, a trailblazing Japanese corporation specialising in assisted reproduction products, and IVF2.0, a leader in AI software for assisted reproductive technology (ART), have joined forces in a strategic collaboration.
The partnership aims to advance real-time sperm selection for intracytoplasmic sperm injection (ICSI), and embryo ranking based on ploidy prediction, ushering in a new era for the IVF market.
Under this agreement, Kitazato will leverage its multi-national distribution network to introduce standardised reproducible data-driven decision-making to IVF laboratories in many regions of the world through IVF2.0’s software.
IVF2.0’s suite of AI tools, including sperm selection (SiD) and embryo selection (ERiCA), assists embryologists in making critical choices to optimize fertility outcomes.
Mr Futoshi Inoue, president and CEO of Kitazato, expresses enthusiasm, stating: “Partnering with IVF2.0 demonstrates our commitment to innovation. We embrace technologies that aim to boost success rates, standardize procedures, and democratize fertility treatment for all.”
Professor Andrew Drakeley, co-founder and board chair of IVF2.0, emphasises the significance of the collaboration.
He said: “Our bond with Kitazato, a prestigious company with world-class products, underscores the growing need for implementing AI tools in IVF clinics globally. This marks a substantial step in the right direction.”
Kitazato, Kitazato – Quality Results for Life (kitazato-ivf.com), renowned for delivering quality products in assisted reproduction, aligns with IVF2.0’s mission to enhance IVF outcomes through AI.
IVF2.0’s innovative software platform employs AI and computer vision technology to elevate key steps in the IVF process.
Learn more at IVF 2.0 (ivf20.ai)
- Femtech must acknowledge the risk of perpetuating medical racism, say campaigners
- US start-up raises US$4.3m to address maternal mental health
- ‘Women crave the quick fix of a silver bullet’: menopause experts have their say on talking therapies
- ‘I cried tears of relief’ – survey reveals the reality of diagnosis delays for women with endometriosis
- Swedish femtech start-up to join acceleration programme in Copenhagen
Receive updates from Femtech World
- News4 weeks ago
Investment fund backs innovation hub to raise awareness of overlooked sexual health conditions
- News2 weeks ago
Venture capital firm closes US$14.5m fund to invest in solutions for underserved populations
- Fertility3 weeks ago
How we can address the gender imbalance in fertility testing
- News1 week ago
NIH grants US$2.3m to evaluate blood pressure monitor during pregnancy
- News3 weeks ago
Researchers develop smart earring to monitor skin temperature
- News4 days ago
New treatment could ‘disrupt’ growth of breast cancer tumours
- News4 weeks ago
Start-up raises US$3.7m in seed funding for smart baby monitor
- News2 weeks ago
UK hospital launches ‘world-first’ endometriosis study